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Abstract Our work aimed to provide a topographical
analysis of all known ionotropic P2X1–7 and metabotropic
P2Y1,2,4,6,11–14 receptors that are present in vivo at the
protein level in the basal ganglia nuclei and particularly in
rat brain slices from striatum and substantia nigra. By
immunohistochemistry-confocal and Western blotting tech-
niques, we show that, with the exception of P2Y11,13
receptors, all other subtypes are specifically expressed in
these areas in different amounts, with ratings of low (P2X5,6
and P2Y1,6,14 in striatum), medium (P2X3 in striatum and
substantia nigra, P2X6,7 and P2Y1 in substantia nigra) and
high. Moreover, we describe that P2 receptors are localized
on neurons (colocalizing with neurofilament light, medium
and heavy chains) with features that are either dopaminer-
gic (colocalizing with tyrosine hydroxylase) or GABAergic
(colocalizing with parvalbumin and calbindin), and they are
also present on astrocytes (P2Y2,4, colocalizing with glial
fibrillary acidic protein). In addition, we aimed to investi-
gate the expression of P2 receptors after dopamine
denervation, obtained by using unilateral injection of 6-
hydroxydopamine as an animal model of Parkinson’s
disease. This generates a rearrangement of P2 proteins:
most P2X and P2Y receptors are decreased on GABAergic
and dopaminergic neurons, in the lesioned striatum and
substantia nigra, respectively, as a consequence of dopami-
nergic denervation and/or neuronal degeneration. Conversely,
P2X1,3,4,6 on GABAergic neurons and P2Y4 on astrocytes
augment their expression exclusively in the lesioned sub-
stantia nigra reticulata, probably as a compensatory reaction
to dopamine shortage. These results disclose the presence of
P2 receptors in the normal and lesioned nigro-striatal circuit,
and suggest their potential participation in the mechanisms
of Parkinson’s disease.
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Abbreviations
BG Basal ganglia
GABA γ-Aminobutyric acid
GFAP Glial fibrillary acidic protein
NF-L Neurofilament-L protein
6-OHDA 6-Hydroxydopamine
MBP Myelin basic protein
P2r P2 receptors
SN Substantia nigra
SNC Substantia nigra pars compacta
SNR Substantia nigra pars reticulata
TH Tyrosine hydroxylase
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It is now well established that the arrangement of ionotropic
P2X and metabotropic P2Y receptors [1, 2] on a cell
membrane is a very dynamic process, often related to
developmental or physiopathological conditions. Moreover,
it is common knowledge that multiple P2 proteins are
simultaneously recruited on a cell membrane for triggering
biological functions. As a consequence, P2 receptors are
rightly considered more than the sum of their single entities
and must be therefore regarded as a complex network of
cooperating receptors. Under this perspective, a numerical
model was also introduced, the combinatorial receptor web
model, which explains the biological efficacy of combining
an assorted array of different P2 proteins on a given cell, in
order to integrate, upgrade, guarantee and optimize specific
receptor-dependent functions [3].
This trend of course applies to the central nervous system
(CNS) as well, where in situ hybridization of P2 mRNA
subtypes and immunohistochemistry of P2 proteins shows, for
instance, wide but heterogeneous simultaneous distribution of
both P2X [4–11]a n dP 2 Y[ 12–15]c l a s s e so fr e c e p t o r s .I n
particular, P2X2,4,6 and P2Y1 subtypes are abundant and
widespread approximately in the entire brain, while P2X1
protein is enriched in the cerebellum, P2X3 in the brain stem,
and P2X7 is largely prejunctional. The hippocampus concur-
rently expresses all P2X and, moreover, P2Y1,2,4,6,12 receptor
subtypes. Particularly in the basal ganglia (BG), neostriatal
medium-spiny neurons and cholinergic interneurons highly
express P2X2 and P2Y1 receptors, but it appears that they
become functional only under certain, as yet unknown,
conditions [16]. Moreover, P2X2 receptor protein was
described in substantia nigra pars compacta (SNC) [17],
whereas both protein and mRNA were described in SNC and
striatum [18]. Finally, only very low levels of P2X4,6 mRNAs
were detected in substantia nigra (SN) and striatum [19].
By functional analysis, ATP release was demonstrated
from cultured embryonic neostriatal neurons [20], and ATP-
evoked potassium currents in rat striatal neurons were
shown to be mediated by P2 receptors [21]. ATP was also
proved to increase extracellular dopamine levels in rat
striatum through stimulation of P2Y subtypes [22],
although it was claimed to inhibit dopamine release in the
neostriatum [23]. Extracellular ATP via P2 receptors was
finally reported to induce neurotoxicity in vitro [24] and in
vivo [25] in the striatum. Besides P2 receptors on neurons,
in BG there is also evidence of P2 receptors on, and release
of ATP from, glial cells. P2Y12 subtype is present, for
instance, on oligodendrocytes in striatum and SN [26], and
P2X7 receptor is upregulated on microglia in striatum after
middle cerebral artery occlusion [27]. In spite of these
results, there is a general paucity of studies addressing the
cellular distribution of all P2 receptor proteins in BG.
Our work thus aimed to provide the complete topo-
graphical analysis of known P2X and P2Y subtypes that are
present in rat striatum and SN in vivo, and to investigate the
dynamic presence of P2 proteins after the induction of
experimental parkinsonism by dopamine-denervation
achieved by using the unilateral 6-hydroxydopamine (6-
OHDA) rat model. By upgrading the current map of P2
receptors expressed in the brain, our study discloses the
potential impact of these receptors in the normal and
lesioned nigro-striatal circuit.
Materials and methods
Histological procedures
Wistar rats (Harlan, Udine, Italy) were anesthetized by i.p.
injections of sodium pentobarbital (60 mg/kg), and trans-
cardially perfused with saline (0.9 % NaCl) followed by 4%
paraformaldehyde, in phosphate buffer (PB, 0.1 M pH 7.4).
Each brain was immediately removed, post-fixed in the
same fixative for 2 h, and then transferred to 30% sucrose
in PB at 4°C, until it sank. The experimental protocol used
in this study was approved by the Italian Ministry of Health
and was in agreement with the guidelines of the European
Communities Council Directive of November 24, 1986 (86/
609/EEC) for the care and use of laboratory animals. All
efforts were made to minimize the number of animals used
and their suffering.
Double immunofluorescence
Transverse sections (40-μm thick) were cut on a freezing
microtome and were processed for double immunofluores-
cence studies. Non-specific binding sites were blocked with
10% normal donkey serum in 0.3% Triton X-100, in
phosphate buffered saline (PBS) for 30 min at room
temperature. The sections were incubated in a mixture of
primary antisera for 24–48 h in 0.3% Triton X-100 in PBS.
Rabbit anti-P2r (1:300, Alomone, Jerusalem, Israel) was
used in combination with either mouse anti-calbindin-D-28K
(1:200, Sigma, Mi, Italy), mouse anti-tyrosine hydroxylase
(TH, 1:500, Sigma), mouse anti-parvalbumin (1:200, Chem-
icon International, Temecula, CA, USA), mouse anti-glial
fibrillary acidic protein (GFAP) (1:400, Sigma), mouse anti-
myelin basic protein (MBP, 1:200, Chemicon International),
mouse anti-neurofilament H non-phosphorylated (SMI 32,
1:500, Sternberger Monoclonals, Lutherville, MD, USA),
mouse anti-neurofilament H and M non-phosphorylated
(SMI 33, 1:500, Sternberger Monoclonals), mouse anti-
neurofilament 160 (NF160, 1:500, Sigma) or goat anti-
neurofilament-L protein (NF-L, 1:100, Santa Cruz, Mi,
Italy). The secondary antibodies used for double labeling
390 Purinergic Signalling (2007) 3:389–398were Cy3-conjugated donkey anti-rabbit IgG (1:100, red
immunofluorescence, Jackson Immunoresearch, West Balti-
more Pike, PA, USA), Cy2-conjugated donkey anti-mouse
IgG (1:100, green immunofluorescence, Jackson Immuno-
research) or Cy2-conjugated donkey anti-goat IgG (1:100,
green immunofluorescence, Jackson Immunoresearch).
The sections were washed in PBS three times for 5 min
each, and then incubated for 3 h in a solution containing a
mixture of the secondary antibodies in 1% normal donkey
serum in PBS. After rinsing, the sections were mounted on
slide glasses, allowed to air dry and coverslipped with gel/
mountanti-fadingmedium(Biomeda,Foster City,CA,USA).
Confocal microscopy
Double- or triple-label immunofluorescence was analyzed
by means of a confocal laser scanning microscope (CLSM)
(LSM 510, Zeiss, Arese, Mi, Italy) equipped with argon
laser emitting at 488 nm, helium/neon laser emitting at
543 nm, and helium/neon laser emitting at 633 nm.
Specificity of the antibodies was positively proved by
performing confocal analysis in the absence of the primary
antibodies, but in the presence of either anti-rabbit or anti-
mouse secondary antibodies. Specificity was further con-
firmed for the P2r antiserum by performing immunoreactions
in the simultaneous presence of the P2r neutralizing immu-
nogenic peptides.
Isolation of cerebral areas and protein extraction
Wistar rats were anesthetized by i.p. injections of sodium
pentobarbital (60 mg/kg) and, after decapitation, brains
were removed. Each brain was transversally cut on a
vibratome (300 μm). The specific cerebral areas were
isolated with the aid of a dissection microscope and
homogenized in RIPA buffer (1% Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% SDS in PBS containing
protease inhibitors). After short sonication, the homoge-
nates were incubated on ice for 1 h and centrifuged at
14,000 r.p.m. for 10 min at 4°C. Protein quantification was
performed in the supernatants by Bradford colorimetric
assay (Biorad, Milan, Italy).
Western blot analysis
Equal amounts of cell lysate (20–30 μg of protein from
each cerebral area) were separated by electrophoresis on
10–12% SDS-PAGE and transferred to nitrocellulose
membranes Hybond-C extra (Amersham Biosciences,
Cologno Monzese, Italy). The filters were pre-wetted in
5% non-fat milk in TBS-T (10 mM Tris pH 8, 150 mM
NaCl, 0.1% Tween 20) and hybridized overnight with
P2X1,2,4 antisera (Alomone, 1:500), P2X5 and P2Y4/14
(1:200), P2Y6 (1:300) or P2Y2 (1:400). The antisera were
immunodetected with an anti-rabbit HRP-conjugated anti-
body (1:5,000) and developed by ECL chemiluminescence
(Amersham Biosciences), using Kodak Image Station
(KDS IS440CF).
Anti-P2r specificity
The polyclonal P2r antisera used in this study were raised
against P2r highly purified peptides (identity confirmed by
mass spectrography and amino acid analysis, as indicated in
the certificate of analysis provided by the manufacturer),
corresponding to specific epitopes not present in any other
known protein. The specificity of the P2r signals was
moreover assessed by incubating Western blots either in the
absence of the primary antiserum, or in the presence of the
primary antiserum together with the neutralizing P2r
immunogenic peptides (μg protein ratio 1:1 between
peptide and antiserum).
6-OHDA lesion and Nissl staining
Deeply anesthetized rats (45 days old, about 150 g body
weight) were injected with 8 μg/4 μl 6-OHDA in saline
0.1% ascorbic acid in the medial forebrain bundle (stereo-
taxic coordinates ap=−4.4; l=+1.2; vd=−7.8, see also
Paxinos et al. [28]) at a rate of 0.38 μl/min. Fifteen days
later, the lesioned rats were tested with 0.05 mg/kg s.c. of
the D1/D2 dopamine agonist apomorphine, in order to
verify the efficacy of the 6-OHDA lesion, and contralateral
turns to the lesion were counted for 40 min. Only those rats
that made at least 200 contralateral turns were used for the
study. It has been previously demonstrated that rats meeting
this screening criterion have greater than 95% depletion of
striatal dopamine [29]. At 1.5 months after the 6-OHDA
lesion, rats were used for immunohistological experiments
(n=3). In order to evaluate cell damage, 40-μm rat brain
sections were mounted onto gelatinized slides. They were
dehydrated through alcohols, and then rehydrated and
stained in 2% cresyl violet for 45 min. Following deionized
water rinses, the slides were dehydrated in a standard
alcohol series, cleared in xylene, and coverslipped.
Results
P2X and P2Y receptor proteins in rat striatum
We describe in this work the cellular and subcellular in vivo
distribution of P2X and P2Y receptors in transverse
sections of adult rat striatum, showing by double immuno-
fluorescence confocal analysis that the various P2 subtype
proteins are distinguished by different degrees of expres-
Purinergic Signalling (2007) 3:389–398 391Fig. 1 P2X and P2Y receptor proteins in rat striatum. Transverse
sections through the striatum of adult rats were processed for double
immunofluorescence studies. Rabbit polyclonal antisera against P2X1,2,4
and P2Y4 receptors (red Cy3 immunofluorescence) were used in
combination with antibodies against neuronal or glial markers (green
Cy2 immunofluorescence). Panel A P2X1: confocal images illustrate
clear colocalization of P2X1 receptor with neurofilament-light protein
(NF-L). The merged field of inset a shows absence of colocalization
between the neuronal GABAergic marker calbindin (green) (a calcium-
binding protein expressed mainly in medium spiny neurons of the
striatum) and P2X1 receptor (red). The merged field of inset b shows the
merged field of P2X1 (red) and MBP (green) overlapping immunor-
eactivities at higher magnification. Panel B P2X2: double immunofluo-
rescence demonstrates that P2X2 receptor immunoreactivity (red)
colocalizes with calbindin protein (green). The insets e and f show
colocalization with the neuronal GABAergic marker parvalbumin
(green) (a calcium-binding protein that is expressed in interneurons of
the striatum). Panel C P2X4: red immunofluorescence for P2X4 protein
merges with the green signals of the three types of neurofilament
proteins: NF-L (inset g, merged field), NF160 (inset i, merged field) and
SMI 32 and, moreover, with parvalbumin (inset h, merged field) and
calbindin (inset i, merged field). Panel D P2Y4: red P2Y4 immunore-
activity is present on calbindin-positive neurons (green), on parvalbu-
min-positive neurons (green) (insets n–q), and on GFAP-positive
astrocytes (inset o, merged field). Western blot analysis also confirms
the presence of receptor proteins P2X1,2,4 (insets c in panel A, d in panel
B, m in panel C, respectively) and P2Y4 (inset r in panel D)i ns t r i a t u m .
Specificity of the P2 receptor signals was assessed by incubations of the
primary antisera with the corresponding neutralizing immunogenic
peptides (μg protein ratio 1:1 between peptide and antiserum). Scale
bars are 10 μmi nA;1 0 0μmi ni n s e ta;2μm in inset b;5 0μmi nB
and in insets e and f;2 0μmi nC;1 0μmi ni n s e t sh, i, l;5μmi ni n s e tg;
50 μmi nD;5μmi ni n s e tn;a n d2 0μm in inset o. Similar results were
obtained in at least four independent experiments
392 Purinergic Signalling (2007) 3:389–398sion and are not uniformly distributed throughout the entire
tissue (Fig. 1).
In particular, a strong P2X1 receptor immunoreactivity (red)
confers a patchy appearance to the striatum, being localized
mainly in white matter, while sparing the projecting
calbindin-positive GABAergic neurons that are highly
enriched in gray matter (Fig. 1A, inset a, green). Moreover,
P2X1 protein immunofluorescence is present on NF-L
positive, transversally oriented neuronal fibers, although
the merged field provides only partial colocalization
between the two signals (Fig. 1A). In addition, the high
magnification analysis (Fig. 1A, inset b) of P2X1 (red) and
MBP (green) immunoreactive signals shows that P2X1
receptor is surrounded by MBP, proving the presence of
P2X1 protein on myelinated fibers. Due to the close vicinity
of the two signals, overlapping yellow immunofluorescence
is also observed. Finally, P2X1 receptor in striatum is
recognized by Western blot analysis as a single protein
band of 60–65 kDa, additionally abolished in the presence
of the P2X1 receptor–neutralizing immunogenic peptide
(Fig. 1A, inset c).
Conversely, an abundant P2X2 receptor immunoreactivity
(red) is found in gray matter of striatum (Fig. 1B), while
sparing the bundles of white matter. Specific receptor
immunolabeling is present not only on the highly expressed
calbindin-positive projecting GABAergic neurons, but also
on the fewer parvalbumin-positive GABAergic interneu-
rons (Fig. 1B, insets e, f). By Western blot analysis, we
show that P2X2 receptor is present in striatum under two
isoforms of about 45 and 32 kDa, furthermore, it is
abolished in the presence of the P2X2 receptor–neutralizing
immunogenic peptide (Fig. 1B, inset d).
P2X3 receptor immunostaining in striatum is of medium
intensity (Table 1), and mainly localizes on GABAergic
neurons of gray matter (data not shown).
P2X4 receptor signal is instead very copious in white
matter, although present on a few fibers of gray matter as
well (Fig. 1C, red). It partially colocalizes with all types of
heavy-, light- and medium-chain neurofilament proteins
(merged fields): SMI 32 (green), NF-L (inset g), and NF160
(inset i). Moreover, we find P2X4 protein also on
GABAergic interneurons (inset h) and GABAergic spiny
neurons (inset l). By Western blot analysis, we demonstrate
that P2X4 receptor is present in striatum as a single band of
about 60 kDa, moreover, it is abolished in the presence of
the P2X4 receptor–neutralizing immunogenic peptide
(Fig. 1C, inset m).
P2X5,6,7 and P2Y1 receptor immunoreactivities in stria-
tum are very weak (Table 1) in gray matter, although totally
absent from white matter under our experimental conditions
(data not shown).
The P2Y2 receptor is highly expressed in striatum on
axons of white matter and astrocytes of gray matter
(Table 1). Moreover, it is detected as a double protein band
in the 55–65 kDa range (data not shown).
A strong P2Y4 receptor immunoreactivity is present only
in gray matter of striatum, localized on both types of
GABAergic neurons: calbindin-positive (Fig. 1D)a n d
parvalbumin-positive (insets n–q). Nevertheless, the recep-
tors are also widespread throughout the striatum on
astrocytes, as shown by colocalization with the GFAP
marker (inset o). By Western blot analysis, we prove that
P2Y4 receptor is present in striatum as a double band of
about 42 and 85 kDa (inset r), likely corresponding to the
monomeric and dimeric aggregation states of the receptor
[30, 31].
While P2Y6 receptor is barely detectable (Table 1)o n
GABAergic neurons in striatum (data not shown),
P2Y11,13,14 receptor proteins were not identified by any
means under our experimental conditions (Table 1). Finally,
P2Y12 receptor in striatum (Table 1) is abundantly
expressed only on oligodendrocytes and myelin sheets, as
previously shown [26].
P2X and P2Y receptor proteins in substantia nigra
We conducted a parallel analysis on the cellular and
subcellular in vivo distribution of P2X and P2Y receptors
in transverse sections of adult rat SN. We showed by
double immunofluorescence confocal analysis that the
different P2 receptor proteins possess more comparable
levels of expression with respect to the striatum, and are
Table 1 Map of P2 receptor proteins in striatum and substantia nigra
Striatum Substantia nigra
P2X1 +++ +++
P2X2 +++ +++
P2X3 ++ ++
P2X4 +++ +++
P2X5 + +++
P2X6 ++ +
P2X7 ++ ++
P2X1 ++ +
P2X2 +++ +++
P2X4 +++ +++
P2X6 + +++
P2X11 ––
P2X12 +++ +++
P2X13 ––
P2X14 – +++
Relative abundance of all P2X and P2Y receptor proteins was
analyzed by confocal immunofluorescence microscopy, as described
in “Materials and methods”. The intensity of the specific immuno-
staining was scored as follow: – = not detected; + = just sufficient to
evaluate presence and outline of positive cells; ++ = adequate to
assess morphological features of cell bodies and/or cellular processes;
+++ = very bright
Purinergic Signalling (2007) 3:389–398 393also more uniformly, although differently, distributed
throughout the entire SNC and SNR (Fig. 2). In particular,
strong signals for ionotropic P2X2,5 (red, Fig. 2A,B), P2X1,4
(Table 1), metabotropic P2Y6,14 (red, Fig. 2C,D) and P2Y4
(Table 1), or moderate signals for P2X3,6 and P2Y1
receptors (Table 1) are present on dopaminergic neurons
(TH-positive) of SNC. Moreover, P2Y2 and P2Y12 recep-
tors are abundantly expressed in SN (Table 1), but P2Y2 is
expressed on axons and astrocytes, and P2Y12 only on
oligodendrocytes and myelin sheets [26]. Conversely, in
SNR, a weak P2X/Y receptor immunoreactivity is limited
to sparse neuronal bodies, likely identified as GABAergic
neurons by colocalization with parvalbumin (data not
shown). The presence at the tissue level in SN of ionotropic
P2X2,5 (insets a in panel A, and b in panel B of Fig. 2,
respectively) and metabotropic P2Y6,14 (insets c in panel C,
and d in panel D of Fig. 2, respectively) proteins is
confirmed by Western blot analysis performed in all cases
in the presence of specific receptor–neutralizing immuno-
genic peptides. Similarly to the striatum, immunoreactive
signals for P2Y11,13 receptors were not identified by any
means under our experimental conditions (Table 1).
Fig. 2 P2X and P2Y receptor
proteins in rat substantia nigra.
Double immunofluorescence
visualized by confocal analysis
was performed in transverse
sections through the substantia
nigra of adult rats. Strong
signals for ionotropic P2X2,5
and metabotropic P2Y6,14 (red
Cy3 immunofluorescence) are
present on dopaminergic
neurons (TH-positive, green
Cy2 immunofluorescence) of
substantia nigra pars compacta
(SNC), whereas in substantia
nigra pars reticolata (SNR) P2X/
Y immunoreactivity is limited to
sparse neuronal bodies. Western
blot analysis confirms the pres-
ence in substantia nigra of
receptor proteins P2X2,5 (insets
a in panel A, and b in panel B,
respectively) and P2Y6,14 (insets
c in panel C, and d in panel D,
respectively). Specificity of the
P2 receptor signals was assessed
by incubation of the primary
antisera with the corresponding
neutralizing immunogenic
peptides (μg protein ratio 1:1
between peptide and antiserum).
Scale bars in all panels are
50 μm. Similar results were
obtained in at least four
independent experiments
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P2 receptors in striatum and substantia nigra
No contralateral rotation as a sign of motor deficit was
reported in rats before being 6-OHDA-lesioned, but was
instead detected after the lesion rotation (data not shown),
together with loss of dopaminergic TH-positive neurons
only from the ipsilateral hemisphere of SNC (Fig. 3A and
insets a, b).
Concomitantly, we prove that dopamine denervation in
the 6-OHDA-lesioned rat generates a significant and
selective rearrangement of P2 receptor proteins. Whereas
the expression pattern and immunofluorescence intensities
of P2X1,4, P2Y2 (colocalizing with all neurofilaments and
present in white matter on fibers projecting from the
cortex), and P2Y12 (present on oligodendrocytes of white
matter) remain constant in both ipsi- and contralateral
hemispheres after 6-OHDA treatment (as well as in control
animals), all other P2X and P2Y receptors are decreased on
parvalbumin- and calbindin-positive GABAergic neurons
of deafferented ipsilateral striatum (but not contralateral and
in control animals), as measured by semiquantitative
analysis (Table 2)( n=3).
Similarly, all P2X and P2Y receptors are lost in the
lesioned (but not contralateral) substantia nigra pars
compacta, consequent to the degeneration of the majority
of TH-positive dopaminergic neurons (Table 2). Converse-
ly, P2X1 (Fig. 3B) and P2X3,4,6 (Table 2) receptors present
on GABAergic neurons, and P2Y4 receptors on astrocytes
augment their expression only in ipsilateral substantia nigra
Fig. 3 6-Hydroxydopamine
modulates the expression of
selected P2 receptor proteins in
striatum and substantia nigra.
Staining of rat substantia nigra
after 6-hydroxydopamine
treatment. Panel A Conventional
microscopy images of Nissl
staining shows several
dopaminergic neurons (arrows)
in the contralateral control hemi-
sphere, which are lost (asterisks)
in the ipsilateral
lesioned hemisphere. Specific
ipsilateral dopaminergic lesion of
substantia nigra pars
compacta (SNC) was also
visualized by confocal TH-
immunostaining (green) (insets
a, b). Panel B Confocal merged
yellow images show upregula-
tion of P2X1 receptor protein
(red) in parvalbumin-positive
GABAergic neurons (green) in
the lesioned side of substantia
nigra pars reticolata (SNR) of
6-hydroxydopamine-treated rats.
Panel C Confocal merged
yellow images show a drastic
increase in GFAP-positive astro-
cytes (green) in the lesioned side
of 6-hydroxydopamine-treated
rats and, correspondingly, an
augment of P2Y4 signal (red)
(inset c). Scale bars are 100 μm
in A, B and in insets a, b;2 0μm
in C;a n d1 0μmi ni n s e tc.
Similar results were obtained in
at least three independent
experiments
Purinergic Signalling (2007) 3:389–398 395pars reticulata adjacent to the lesioned pars compacta. In
this same area, a phenomenon of astrogliosis is also
induced, as detected by more abundant expression of
GFAP-positive astrocytes (Fig. 3C).
Discussion
Because the roles of ATP in the CNS have received less
attention until recently, often due to lack of appropriate
research tools, our knowledge of the functional qualifica-
tion of P2 receptors in the brain is limited, although rapidly
improving. As a group of nuclei interconnected with
cerebral cortex, thalamus and brainstem, and associated
with a variety of functions, such as motor control,
cognition, emotions and learning, the BG [32] is an area
that deserves thorough analysis. Our work was aimed at
mapping in vivo the presence of P2 receptor subtypes in the
BG nuclei of striatum and SN by immunofluorescence-
confocal and Western blotting techniques. The specificity of
the highly sensitive molecular probes used for the detection
of all known P2X and P2Y receptor proteins has been
previously validated [33, 34]. In addition, we undertook an
analysis that excluded possible cross-reactivity for all
antisera used.
Our results not only establish that the majority of P2X
(P2X1–7) and P2Y (P2Y1,2,4,6,11–14) receptors so far cloned
from mammalian tissues are found in striatum and SN, but
also prove their distinctive localization on neurons and/or
glial cells. In detail we show that, with the exception of
only P2Y11 and P2Y13 receptors (whose immunoreactivity
was not identified by any means under our experimental
conditions), all other subtypes are specifically localized in
striatum and SN (both pars compacta and reticulata),
although with different levels of expression, rated as low
(P2X5,6 and P2Y1,6,14 in striatum), medium (P2X3 in
striatum and SN; P2X6,7 and P2Y1 in SN) and high.
Moreover, while we show a prevalence of P2 receptors on
neurons (P2X1,4 and P2Y2 colocalizing with neurofilament
light, medium and heavy chains) with features that are
either dopaminergic (P2X2–5 and P2Y1,4,6,14 colocalizing
with TH, in SN) or GABAergic (P2X2–4 and P2Y4
colocalizing with parvalbumin and calbindin, in striatum),
we also describe their expression on astrocytes (P2Y2,4 in
striatum and SN, colocalizing with GFAP), microglia
(P2X7, colocalizing with OX42) [27], and oligodendrocytes
(P2Y12, colocalizing with MBP and RIP) [26]. By
confirming previous autoradiographic studies [35, 36], our
results therefore prove the widespread but diversified P2-
receptor protein distribution in striatum and SN, and extend
to these nuclei the great level of biological complexity and
molecular sophistication pertaining to P2 receptors [3].
Although the configuration of receptor subunits required
for assembly into functional cation channels gated by
extracellular ATP in different regions of the CNS compris-
ing the BG is not known yet, colocalization of so many
different P2X subtypes in striatum and SN is definitely
compatible with heteromultimeric assembly of ionotropic
subunits. Since a growing body of biochemical and
biophysical evidence now indicates that the propensity to
form homo- and especially hetero-multimers is frequent
also for G protein-coupled receptors [37] comprising the
P2Y subtypes [30, 31], the concurrent expression in
striatum and SN of as many metabotropic receptors could
explain once more a complex hetero-oligomeric architec-
ture. Nevertheless, the biological phenomenon of redun-
dancy could also justify the simultaneous presence of
multiple P2 receptor subtypes in these nuclei, with the
final outcome of increasing the structural and pharmaco-
logical heterogeneity of these brain regions. Finally, the
composite architecture of P2 receptors that we depicted in
striatum and SN might likely also signify a multipart
mechanism of receptor cooperative behavior (Volonté et al.,
personal communication) that sustains the concomitant
level of complexity of this brain area in several tasks, such
as planning and modulation of movement pathways,
cognitive processes involving executive functions, reward
and addiction. These possibilities are, of course, not
mutually exclusive.
Striatal neurons, including the most abundant medium
spiny neurons, receive convergent synaptic modulation
from nigral dopaminergic neurons and from cortical
Table 2 Map of P2 receptor modulation after dopamine denervation
Ipsilateral Striatum Ipsilateral SN
P2X1 = ↑GABA
P2X2 ↓GABA ↓TH
P2X3 ↓GABA ↓TH, ↑GABA
P2X4 ↓GABA ↓TH, ↑GABA
P2X5 = ↓TH
P2X6 = ↓TH, ↑GABA
P2X7 ==
P2X1 = ↓TH
P2X2 ==
P2X4 ↓GABA ↑GFAP
P2X6 = ↓TH
P2X11 ==
P2X12 ==
P2X13 ==
P2X14 = ↓TH
Relative increase (↑) or decrease (↓) in P2X and P2Y receptor proteins
analyzed by confocal immunofluorascence microscopy in striatum and
SN after treatment in rat in vivo with 6-hydroxydopamine (ipsilateral),
and in control (not lesioned) brain hemisphere (contralateral). TH =
presence in dopaminergic neurons, GABA = presence in GABAergic
neurons, GFAP = presence in astrocytes
396 Purinergic Signalling (2007) 3:389–398glutamatergic projections [38]. The present study showing
that lesions of nigral dopaminergic neurons do not
significantly affect purinergic receptors present on axons
of striatum white matter, but do generate a significant
overall decrease in P2X and P2Y receptor proteins from
striatal spiny neurons and GABAergic interneurons, thus
confirms and extends the involvement of P2 receptors and
extracellular ATP to the cortex-basal ganglia circuit [21].
Since dopaminergic denervation affects not only the
nigrostriatal dopaminergic pathway but, as a consequence,
the corticostriatal glutamatergic pathway with an increase in
glutamatergic transmission [39–41] and extracellular gluta-
mate levels in the striatum [42], the reduced P2 receptor
protein expression that we demonstrate in striatum gray
matter could thus not only be a direct effect of the
nigrostriatal inhibition, but also a cause of de-inhibitory
mechanisms occurring in the corticostriatal circuit. In this
regard, it is common knowledge that extracellular ATP
participates in excitatory neurotransmission in the CNS
[43], that release of extracellular ATP occurs in CNS under
both normal and pathological conditions [44] and, not least,
that glutamate release is induced by extracellular ATP in
CNS glutamatergic neurons [45].
Neurons of the pars compacta responsible for dopamine
production in the brain, which we have shown here to
completely lose their array of P2 receptors as a conse-
quence of neurodegeneration induced by 6-OHDA treat-
ment, receive inhibiting signals also from neurons of the
pars reticulata that produce GABA [46]. Loss of dopamine
neurons in the SNC, one of the main pathological features
of Parkinson’s disease leading to a marked reduction in
dopamine function in the brain, thus also impedes the
inhibitory pathway of SNR, with a consequent overactiva-
tion of GABAergic neurons. Our findings that specific
expression of both ionotropic P2X1,3,4,6 receptors on
GABAergic neurons and metabotropic P2Y4 receptors on
astrocytes is remarkably increased in SNR after dopamine
denervation thus probably reflects a parallel compensatory
overreaction of GABAergic neurons to dopamine shortage.
One possible explanation is that purinergic mechanisms
might thus play a crucial role in the fine-tuned regulation
not only of dopaminergic and glutamatergic cross-talk in
striatum, as it occurs in nucleus accumbens [47], but also of
GABAergic and dopaminergic interplay in SN, as it occurs
in the mesolimbic neuronal circuit [48]. This is consistent
with the overall versatile functions accomplished by P2
receptors in the CNS under both normal and pathological
conditions [43, 44, 49] and, in particular, with the inter-
mediary role in oligodendrocyte-to-neuron [26], Bergmann
glia-to-neuron, and neuron-to-neuron communication [50]
proposed for P2 receptors in various brain regions.
In summary, the importance of our work is twofold. We
first provide the complete topographical analysis of all
known P2X and P2Y receptor subtypes expressed in vivo at
their protein levels in rat striatum and SN, which, when
considered alongside functional studies, supports a key role
for extracellular ATP as a cotransmitter/neuromodulator in
these brain areas. Then, we prove that dopamine denerva-
tion in the 6-OHDA animal model of Parkinson’s disease
generates a significant rearrangement of P2 receptor
proteins in these nuclei, therefore disclosing the participa-
tion of P2 receptors in the lesioned nigro-striatal circuit.
While requiring further investigation, our findings indicate
a potential but noteworthy pharmacological and therapeutic
novel outcome for Parkinson’s disease.
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